Secondaries specialist TR Capital expands into Singapore
Asia-focused secondaries investor TR Capital has opened an office in Singapore, expanding a regional footprint that already includes bases in Hong Kong, Shanghai, Shenzhen, and Mumbai.
Paul Robine, the firm’s founder and CEO, cited both the investment opportunity in Southeast Asia and favourable policies introduced by Singapore intended to cement its position as a financial hub as...
Co-Stone leads $43m round for China biosynthesis player
Co-Stone Capital Management has led a CNY 300m (USD 43m) Series B round for Readline, a Shenzhen-based company that specialises in synthetic biology.
Australia’s Heal Partners closes debut fund on $137m
Australia’s Heal Partners, a health, education, and lifestyle-focused venture capital firm, has closed its first fund on AUD 200m (USD 137m). The target was AUD 100m.
US regulator gets access to Chinese audits
The threat of delisting that has haunted Chinese companies that trade on US exchanges appears to have receded after the US regulators announced they had gained full access to the audits of these companies for the first time.